ArticleCancer management and research2021

Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression.

Xinhua Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.